Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02506023 · ClinicalTrials.gov registry record · Phase 1
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
A Phase 1 study of Hemophilia A, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT02506023 is a Phase 1 study of Hemophilia A that has completed, run by Emory University. The registered enrollment target is 2 participants, below the 92-participant average among 42 other Hemophilia A trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02506023, a Phase 1 study of Hemophilia A, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).
Conditions Studied
Interventions
- DRUG Desmopressin
Study Locations (2)
Georgia
- Children's Hospital of Atlanta Egleston - Atlanta
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02506023
The ClinicalTrials.gov registry entry for NCT02506023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 42 other Hemophilia A trials with a reported enrollment target (98% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Desmopressin is the first listed.
NCT02506023 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02506023 about?
NCT02506023 is a clinical study titled "Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers". The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).
What is the current status of trial NCT02506023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-07. Estimated completion is 2018-06-15.
What conditions does trial NCT02506023 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT02506023?
The interventions under investigation include: Desmopressin (DRUG).
Who is sponsoring clinical trial NCT02506023?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02506023 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
-
ASC618 Gene Therapy in Hemophilia A Patients
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy for Haemophilia A.
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.